Datapoint: Scilex Sues Generic Pain Patch Challenger

Scilex Pharmaceutics, Inc. is suing Apotex Inc. over the Canadian drugmaker’s developing lidocaine patch, a generic challenger to Scilex’s ZTlido. Scilex says Apotex is violating three of ZTlido’s patents, centering around the patch’s non-aqueous lidocaine delivery. In the U.S., ZTlido is approved for the treatment of post-herpetic neuralgia, an indication for which it holds covered or better status for 57% of all insured lives under the pharmacy benefit. 10.6% of covered lives have preferred access to ZTlido without utilization management restrictions.

SOURCE: MMIT Analytics, as of 6/29/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 17

Datapoint: Humana Inks Deal to Acquire Inclusa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 16

Datapoint: Mississippi Unveils Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 15

Datapoint: SCAN Plots MA Expansion Into Texas

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today